Experimental absence seizures: potential role of gamma-hydroxybutyric acid and GABAB receptors
- PMID: 1324978
- DOI: 10.1007/978-3-7091-9206-1_11
Experimental absence seizures: potential role of gamma-hydroxybutyric acid and GABAB receptors
Abstract
We have investigated whether the pathogenesis of spontaneous generalized non-convulsive seizures in rats with genetic absence epilepsy is due to an increase in the brain levels of gamma-hydroxybutyric acid (GHB) or in the rate of its synthesis. Concentrations of GHB or of its precursor gamma-butyrolactone (GBL) were measured with a new GC/MS technique which allows the simultaneous assessment of GHB and GBL. The rate of GHB synthesis was estimated from the increase in GHB levels after inhibition of its catabolism with valproate. The results of this study do not indicate significant differences in GHB or GBL levels, or in their rates of synthesis in rats showing spike-and-wave discharges (SWD) as compared to rats without SWD. Binding data indicate that GHB, but not GBL, has a selective, although weak affinity for GABAB receptors (IC50 = 150 microM). Similar IC50 values were observed in membranes prepared from rats showing SWD and from control rats. The average GHB brain levels of 2.12 +/- 0.23 nmol/g measured in the cortex and of 4.28 +/- 0.90 nmol/g in the thalamus are much lower than the concentrations necessary to occupy a major part of the GABAB receptors. It is unlikely that local accumulations of GHB reach concentrations 30-70-fold higher than the average brain levels. After injection of 3.5 mmol/kg GBL, a dose sufficient to induce SWD, brain concentrations reach 240 +/- 31 nmol/g (Snead, 1991) and GHB could thus stimulate the GABAB receptor. Like the selective and potent GABAB receptor agonist R(-)-baclofen, GHB causes a dose-related decrease in cerebellar cGMP. This decrease and the increase in SWD caused by R(-)-baclofen were completely blocked by the selective and potent GABAB receptor antagonist CGP 35348, whereas only the increase in the duration of SWD induced by GHB was totally antagonized by CGP 35348. The decrease in cerebellar cGMP levels elicited by GHB was only partially antagonized by CGP 35348. These findings suggest that all effects of R(-)-baclofen are mediated by the GABAB receptor, whereas only the induction of SWD by GHB is dependent on GABAB receptor mediation, the decrease in cGMP being only partially so. Taken together with the observations of Marescaux et al. (1992), these results indicate that GABAB receptors are of primary importance in experimental absence epilepsy and that GABAB receptor antagonists may represent a new class of anti-absence drugs.
Similar articles
-
GABAB receptor antagonists: potential new anti-absence drugs.J Neural Transm Suppl. 1992;35:179-88. doi: 10.1007/978-3-7091-9206-1_12. J Neural Transm Suppl. 1992. PMID: 1324979
-
Presynaptic gamma-hydroxybutyric acid (GHB) and gamma-aminobutyric acidB (GABAB) receptor-mediated release of GABA and glutamate (GLU) in rat thalamic ventrobasal nucleus (VB): a possible mechanism for the generation of absence-like seizures induced by GHB.J Pharmacol Exp Ther. 1995 Jun;273(3):1534-43. J Pharmacol Exp Ther. 1995. PMID: 7791129
-
Relation of the [3H] gamma-hydroxybutyric acid (GHB) binding site to the gamma-aminobutyric acidB (GABAB) receptor in rat brain.Biochem Pharmacol. 1996 Oct 25;52(8):1235-43. doi: 10.1016/0006-2952(96)00477-7. Biochem Pharmacol. 1996. PMID: 8937431
-
GHB receptor targets in the CNS: focus on high-affinity binding sites.Biochem Pharmacol. 2014 Jan 15;87(2):220-8. doi: 10.1016/j.bcp.2013.10.028. Epub 2013 Nov 20. Biochem Pharmacol. 2014. PMID: 24269284 Review.
-
Genetic absence epilepsy in rats from Strasbourg--a review.J Neural Transm Suppl. 1992;35:37-69. doi: 10.1007/978-3-7091-9206-1_4. J Neural Transm Suppl. 1992. PMID: 1512594 Review.
Cited by
-
γ-Hydroxybutyrate (GHB)-induced respiratory depression: combined receptor-transporter inhibition therapy for treatment in GHB overdose.Mol Pharmacol. 2012 Aug;82(2):226-35. doi: 10.1124/mol.112.078154. Epub 2012 May 4. Mol Pharmacol. 2012. PMID: 22561075 Free PMC article.
-
The GABAB-receptor antagonist, CGP 35348, antagonises gamma-hydroxybutyrate- and baclofen-induced alterations in locomotor activity and forebrain dopamine levels in mice.J Neural Transm (Vienna). 1996;103(11):1255-63. doi: 10.1007/BF01271186. J Neural Transm (Vienna). 1996. PMID: 9013412
-
Behavioral effects of gamma-hydroxybutyrate in humans.Behav Pharmacol. 2010 Jul;21(4):332-42. doi: 10.1097/FBP.0b013e32833b3397. Behav Pharmacol. 2010. PMID: 20526195 Free PMC article. Clinical Trial.
-
GABAB Receptor Chemistry and Pharmacology: Agonists, Antagonists, and Allosteric Modulators.Curr Top Behav Neurosci. 2022;52:81-118. doi: 10.1007/7854_2021_232. Curr Top Behav Neurosci. 2022. PMID: 34036555 Review.
-
gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness.CNS Drugs. 2006;20(12):993-1018. doi: 10.2165/00023210-200620120-00004. CNS Drugs. 2006. PMID: 17140279 Review.
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical
Miscellaneous